Ballerup, Denmark, February 23, 2026 – LEO Pharma today announced that Kasper Fangel, CEO of ISS A/S, will be nominated for election as a member of the Board of Directors at the Annual General Meeting (AGM) on 25 February 2026 and subsequently appointed as Chair of the Audit Committee.

A Danish national, Kasper Fangel has built a distinguished career in corporate leadership and finance. At ISS A/S, one of the world’s largest workplace experience and facility management companies, he has played a pivotal role in shaping strategy and delivering sustainable performance on a global scale - serving in various leadership roles, including CFO from 2020 and CEO since 2023. His extensive expertise in governance, financial oversight, capital allocation, and strategic execution will be a valuable asset to LEO Pharma’s Board as the company advances its journey of sustainable growth and innovation in medical dermatology.

"We are delighted to welcome Kasper to the Board and as our new Chair of the Audit Committee. With more than 15 years of leadership experience at ISS and most recently as both CFO and CEO, combined with his financial acumen, growth mindset, and proven leadership abilities, we are confident that he, together with the rest of the Board, will successfully guide LEO Pharma through the next phase of its strategic journey," said Jesper Brandgaard, Chair of LEO Pharma’s Board of Directors.

This nomination follows the decision by Lars Green, current Chair of the Audit Committee, not to seek re‑election at the AGM in 2026. Lars has chosen to focus on his other board responsibilities. He has served on LEO Pharma’s Board of Directors since 2021.

Jesper Brandgaard added: "On behalf of the Board, I would like to thank Lars for his leadership and significant commitment over the past years. His contribution has had an immensely positive impact, and LEO Pharma is in a far stronger position today thanks to his efforts. We wish Lars the very best in his future endeavors."

As part of the upcoming AGM, new employee‑elected board members (Signe Maria Christensen (re-elected), Allan Carsten Dahl, Thomas Facius, and Franck Maréno (re-elected)) will also join the Board for a four‑year election period starting 25 February 2026.